Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Borg

Showing results (171-180 of 224) with videos related to

Pageof 23
Sort By:
Clinics and Research in Hepatology and Gastroenterology|May 24, 2024
Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancerNicolas Cazeneuve, Olivier Bouché, Julie Leger, et al.
Cancer Medicine|June 1, 2023
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study resultsFortunato Ciardiello, Yung-Jue Bang, Andrés Cervantes, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 4, 2020
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II studyViolaine Randrian, Antoine Adenis, Jérôme Desrame, et al.
Cellular & Molecular Immunology|January 30, 2023
CD8<sup>+</sup> CD226<sup>high</sup> T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgeryJulien Viot, Syrine Abdeljaoued, Angélique Vienot, et al.
Oncoimmunology|February 5, 2019
Circulating NKp46<sup>+</sup> Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung CancerEmilie Picard, Yann Godet, Caroline Laheurte, et al.
The Journal of Investigative Dermatology|February 2, 2016
Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient PrognosisNicolas Jacquelot, María Paula Roberti, David P Enot, et al.
JAMA Oncology|August 3, 2023
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical TrialJulien Taïeb, Olivier Bouche, Thierry André, et al.
Future Oncology (London, England)|November 12, 2024
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancerJean-David Fumet, Nicolas Roussot, Aurélie Bertaut, et al.
Ebiomedicine|May 17, 2025
Deciphering human endogenous retrovirus expression in colorectal cancers: exploratory analysis regarding prognostic value in liver metastasesJulien Viot, Romain Loyon, Nawfel Adib, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 2, 2021
Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practiceGuillaume Mouillet, Antoine Falcoz, Joëlle Fritzsch, et al.
Pageof 23

Showing results (171-180 of 224) with videos related to

Sort By:
Pageof 23
Clinics and Research in Hepatology and Gastroenterology|May 24, 2024
Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancerNicolas Cazeneuve, Olivier Bouché, Julie Leger, et al.
Cancer Medicine|June 1, 2023
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study resultsFortunato Ciardiello, Yung-Jue Bang, Andrés Cervantes, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 4, 2020
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II studyViolaine Randrian, Antoine Adenis, Jérôme Desrame, et al.
Cellular & Molecular Immunology|January 30, 2023
CD8<sup>+</sup> CD226<sup>high</sup> T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgeryJulien Viot, Syrine Abdeljaoued, Angélique Vienot, et al.
Oncoimmunology|February 5, 2019
Circulating NKp46<sup>+</sup> Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung CancerEmilie Picard, Yann Godet, Caroline Laheurte, et al.
The Journal of Investigative Dermatology|February 2, 2016
Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient PrognosisNicolas Jacquelot, María Paula Roberti, David P Enot, et al.
JAMA Oncology|August 3, 2023
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical TrialJulien Taïeb, Olivier Bouche, Thierry André, et al.
Future Oncology (London, England)|November 12, 2024
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancerJean-David Fumet, Nicolas Roussot, Aurélie Bertaut, et al.
Ebiomedicine|May 17, 2025
Deciphering human endogenous retrovirus expression in colorectal cancers: exploratory analysis regarding prognostic value in liver metastasesJulien Viot, Romain Loyon, Nawfel Adib, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 2, 2021
Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practiceGuillaume Mouillet, Antoine Falcoz, Joëlle Fritzsch, et al.
Pageof 23